Dr. Rugo on SWISH Trial for HR-Positive Breast Cancer

Dr. Hope Rugo – ESMO 2022 – Exploring the latest trial data & advances in breast cancer treatmentsПодробнее

Dr. Rugo on the Advances in the Treatment of HER2-Positive Breast CancerПодробнее

Dr. Rugo on Guidelines for the Treatment of Metastatic Breast CancerПодробнее

Dr. Rugo on Ongoing Trials in HER2+ Breast CancerПодробнее

Dr. Rugo on Anti-Angiogenesis Therapy Response PredictorsПодробнее

Dr. Rugo on Chemotherapy for Metastatic Breast CancerПодробнее

Dr. Rugo on Extended Adjuvant Hormone Therapy for Breast CancerПодробнее

Dr. Rugo on the Phase III SOPHIA Trial in HER2+ Breast CancerПодробнее

Dr. Rugo on the Significance of the MONARCH I Trial for Breast CancerПодробнее

Dr. Rugo Discusses MONARCH I in HR+ HER2- Breast CancerПодробнее

Dr. Rugo on Resistance to CDK4/6 Inhibitors in HR+ Breast CancerПодробнее

Dr. Hope Rugo Examines Angiogenesis Inhibition for Advanced Breast CancerПодробнее

Dr. Rugo on the Efficacy of Bevacizumab in Breast CancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

Therapy Approaches in HR+ Breast CancerПодробнее

Dr. Hope Rugo on Trastuzumab Biosimilar in HER2-Positive Breast CancerПодробнее

Dr. Rugo on Hormone Therapy for Patients With Breast CancerПодробнее

Rugo: De-escalating Systemic Therapy for Breast CancerПодробнее

Dr. Hurvitz on neoMONARCH Trial for HR+ Breast CancerПодробнее